Explore the rising trend of GLP-1 weight loss drugs, their impact on obesity, costs, and potential generics entering the market.

The race to develop the next generation of weight loss drugs has taken an interesting new turn. In recent research, Eli Lilly ...

Eli Lilly and Novo Nordisk May Soon Sell Weight Loss Drugs on the Planned TrumpRx. Could This Further Boost the Healthcare ...

Novo Nordisk A/S remains attractive with strong cash flow and robust pipeline. Click here to read why NVO stock is a Buy.

Wegovy and Zepbound are 2 FDA-approved injectables for weight loss. Learn how they compare in benefits, side effects, and ...

When the weather outside gets colder, our( bodies instinctively hunt for extra energy (in the form of food) to maintain core ...

In a 71-week, double-blind study, Nova Nordisk—creators of the popular weight loss drug Wegovy—says their oral semaglutide ...

Novo Nordisk has cut prices of its weight-loss drug Wegovy by up to 37% in India. This move intensifies competition with Eli ...

Oregon and federal leaders must take a dual approach: Expanding safe, affordable access to FDA-approved anti-obesity ...

Drugmaker Eli Lilly said it would soon start late-stage trials for eloralintide, a drug mimicking the pancreatic hormone amylin that slows digestion and reduces hunger.

Below, doctors explain everything you need to know about the phenomenon. It’s important to be clear upfront that “Ozempic ...

Medicare will cover GLP-1 weight loss drugs for specific patient groups, beginning in mid-2026, under a deal struck with drugmakers.